statistiche ricercatore

Continente	#
NA - Nord America	696
AS - Asia	466
EU - Europa	373
SA - Sud America	80
AF - Africa	8
Continente sconosciuto - Info sul continente non disponibili	1
OC - Oceania	1
Totale	1.625

Nazione	#
US - Stati Uniti d'America	665
SG - Singapore	174
IT - Italia	140
VN - Vietnam	120
CN - Cina	78
BR - Brasile	59
HK - Hong Kong	48
DE - Germania	46
SE - Svezia	40
RU - Federazione Russa	39
IE - Irlanda	35
CA - Canada	21
GB - Regno Unito	13
ES - Italia	12
FI - Finlandia	9
MX - Messico	8
NL - Olanda	8
PL - Polonia	8
AR - Argentina	7
FR - Francia	7
ID - Indonesia	7
IN - India	7
ZA - Sudafrica	7
BD - Bangladesh	6
KR - Corea	6
EC - Ecuador	4
JP - Giappone	4
VE - Venezuela	4
AT - Austria	3
PK - Pakistan	3
TR - Turchia	3
AE - Emirati Arabi Uniti	2
BE - Belgio	2
CH - Svizzera	2
CZ - Repubblica Ceca	2
JO - Giordania	2
MY - Malesia	2
PE - Perù	2
RS - Serbia	2
A2 - ???statistics.table.value.countryCode.A2???	1
AL - Albania	1
AU - Australia	1
AZ - Azerbaigian	1
BB - Barbados	1
CL - Cile	1
KG - Kirghizistan	1
MA - Marocco	1
NO - Norvegia	1
NP - Nepal	1
PA - Panama	1
PT - Portogallo	1
PY - Paraguay	1
RO - Romania	1
SR - Suriname	1
TH - Thailandia	1
UA - Ucraina	1
UY - Uruguay	1
Totale	1.625

Nome	#
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities	374
High throughput molecular characterization of normal karyotype acute myeloid leukemia in the context of the prospective trial 02/06 of the northern italy leukemia group (NILG)	268
Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06	237
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation	205
Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience	198
Carcik-CD19 Cells Expand In Vivo Toward a CD8+ Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response	193
Skip pattern approach toward the early access of innovative anticancer drugs	173
Totale	1.648

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	132	0	0	0	0	0	31	15	17	21	15	16	17
2021/2022	120	12	19	15	12	13	10	7	2	5	4	7	14
2022/2023	162	20	40	24	11	7	23	5	13	12	0	4	3
2023/2024	86	4	3	1	9	7	26	19	2	5	1	0	9
2024/2025	373	8	16	12	13	18	10	22	5	23	39	29	178
2025/2026	681	146	66	80	158	186	45	0	0	0	0	0	0
Totale													1.648

Bicocca Open Archive